Sanofi: First-quarter 2018 Business EPS(1) up 1.4% at CER

    NEXT STORY
    FIT Biotech Oy: APPOINTMENT OF TOMMI HOLOPAINEN AS CFO AND AS A MEMBER OF THE MANAGEMENT TEAM OF FIT BIOTECH
    PREV STORY
    ThromboGenics Initiates Phase 2 Clinical Study Evaluating anti-PlGF (THR-317) in combination with anti-VEGF (ranibizumab) for treatment of Diabetic Macular Edema (DME)
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Vical Completes Target Enrollment in Its Phase 2 Therapeutic HSV-2 Vaccine Trial

    SAN DIEGO, April 19, 2017 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) announced today that ...

    author_avatar
    NASDAQ Market News

    Asterias Biotherapeutics to Present Safety and Efficacy Data from AST-OPC1 SCiStar Study at the American Spinal Injury Association (ASIA) 2018 Annual Meeting                                                                         

    FREMONT, Calif., May 02, 2018 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE MKT:AST), a ...

    author_avatar
    NASDAQ Market News

    RedHill Biopharma Announces Positive Top-Line Results from Phase III Study of RHB-104 in Crohn’s Disease

    Primary endpoint successfully achieved - superior remission rate at week 26 in patients treated ...

    author_avatar
    NASDAQ Market News